Canaccord keeps USD 5.50 target for Clover Health stock
Published on 10/15/2026 at 21:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and quarterly growth
- Canaccord Genuity maintained a USD 5.50 target on October 9, 2026.
- Second-quarter 2026 revenue rose 56.00 percent to USD 743.17 million.
- Clover Health stock costs EUR 4.18 at Lang & Schwarz on October 15, 2026 at 9:34 p.m. CEST, down 2.09 percent versus the Nasdaq prior close.
- Clover Health will report third-quarter 2026 results on November 4, 2026.
Clover Health (ISIN US18914F1030) remained under a USD 5.50 target from Canaccord Genuity, which maintained its Buy rating on October 9, 2026. At the Nasdaq price of USD 4.69, the target stood 17.27 percent higher. Clover Health stock was trading at EUR 4.18 at Lang & Schwarz on October 15, 2026 at 9:34 p.m. CEST, down 2.09 percent against the Nasdaq prior close.
Revenue growth remains substantial
Clover's second-quarter 2026 revenue reached USD 743.17 million, up 56.00 percent from the second quarter of 2025. The company also reported USD 28.00 million in GAAP net income and USD 41.00 million in adjusted EBITDA for the quarter, according to Yahoo Finance.
Stock stays below its yearly high
The Nasdaq quote stood at USD 4.69 at 3:37 p.m. ET on October 15, 2026. The 52-week range was USD 1.58 to USD 5.59, putting the stock 16.10 percent below its high. Trading volume reached 2,610,432 shares against an average of 4,303,104 shares. Clover Health's market capitalization was USD 2.5 billion.
Target and reporting date
The Canaccord Genuity target of USD 5.50 was reported by Markets Insider on October 9, 2026. The target is 17.27 percent above the Nasdaq price of USD 4.69. Clover Health's next earnings conference call is scheduled for November 4, 2026, at 5:00 p.m. EST, according to Clover Health.
Current market position
The company operates in healthcare and provides Medicare Advantage plans supported by its Clover Assistant software platform. Its second-quarter revenue and net income figures give the stock a stronger operating reference than the price move alone, while the 52-week distance keeps the current valuation in a broad market context.
Price and investor reference
Clover Health was trading at EUR 4.18 at Lang & Schwarz on October 15, 2026 at 9:34 p.m. CEST, down 2.09 percent versus the Nasdaq prior close. The Nasdaq price was USD 4.69 at 3:37 p.m. ET on October 15, 2026.
The further course of trading is shown by the continuously updated real-time quote of Clover Health stock.
Clover Health market data
- Company: Clover Health Investments, Corp.
- ISIN: US18914F1030
- Ticker: CLOV
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 9:34 p.m. CEST): EUR 4.18
- Change versus Nasdaq prior close: minus 2.09 percent
- Market capitalization: USD 2.5 billion (as of October 15, 2026)
- 52-week range: USD 1.58-USD 5.59 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical - Healthcare Plans
- Next earnings date: November 4, 2026
Market context: Market report Nasdaq Composite.
